Vor Biopharma shares surge 10.08% after-hours on Telitacicept Phase 3 success and JPMorgan conference participation.

Vor Biopharma Inc. surged 10.08% in after-hours trading following its announcement to participate in the 44th Annual J.P. Morgan Healthcare Conference, a key event for biotech firms to engage with investors and analysts. The conference, a platform for showcasing therapeutic pipelines and strategic updates, likely boosted investor optimism about Vor’s prospects, including its telitacicept program for autoimmune diseases. Additional catalysts included recent analyst upgrades (Zacks to "Buy") and positive phase.